Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Cefuroxime (1500mg) + Sulbactam (750mg)
Therapeutic Category
Antibacterials, Antibiotic
Dosage Form
Injection
Packaging Type
Vial + Water
Packaging
2.25mg
Price
₹645/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Cefuzrom S 2.5 Injection is a combination of two powerful active ingredients: Cefuroxime and Sulbactam. Cefuroxime is a broad-spectrum second-generation cephalosporin antibiotic that is highly effective against both Gram-positive and Gram-negative bacterial infections. It works by interfering with bacterial cell wall synthesis, leading to the destruction of the bacteria. Sulbactam is a beta-lactamase inhibitor that enhances the efficacy of Cefuroxime by protecting it from degradation by beta-lactamase-producing bacteria.
This combination makes Cefuzrom S a potent choice in treating various severe bacterial infections, especially in hospital settings. It is indicated for treating infections of the respiratory tract, skin, urinary tract, and soft tissues, among others. The inclusion of Sulbactam helps extend the spectrum of Cefuroxime, making it effective against resistant strains of bacteria that would typically be unaffected by standard cephalosporins.
Common side effects include nausea, diarrhea, rash, and allergic reactions. Serious effects may include liver dysfunction or anaphylaxis.
Cefuzrom S 2.5 Injection is used to treat moderate to severe bacterial infections, including respiratory, urinary tract, skin, and intra-abdominal infections.
Use under medical supervision and follow prescribed dosage carefully.
Store between 2°C to 8°C. Do not freeze. Keep tightly closed and protect from light.
Composition : Cefuroxime (1500mg)
Composition : Cefuroxime (1.5gm)
Composition : Clarithromycin (500mg) Injection
Composition : Clindamycin (300mg) Injection
Composition : Clindamycin (600mg)
Composition : Colistimethate Sodium (1Million IU)
Composition : Colistimethate Sodium (2Million IU)
Composition : Doxycycline (100mg) + Vitamin C (100mg)
Composition : Meropenem (1000mg) Injection
Composition : Meropenem (1000mg) + Sulbactam (500mg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Cefuroxime 1500 mg + Sulbactam 750 mg Injection is a broad-spectrum antibiotic and beta-lactamase inhibitor combination used for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, gynecological infections, bone and joint infections, and post-surgical infections. Sulbactam enhances the effectiveness of Cefuroxime against resistant bacteria. It is a strong anti-infective and hospital injectable segment product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand from hospitals, surgeons, physicians, gynecologists, and critical-care specialists. Antibiotic injectables are among the most prescribed hospital products, ensuring regular institutional procurement and repeat orders.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in antibiotic, critical-care, and hospital injectable segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and institutional suppliers benefit from strong hospital demand, surgical prophylaxis usage, infection management protocols, and continuous prescription volume, making it a stable and high-value pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in antibiotic and hospital injectable formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the anti-infective and critical-care segment.